Close menu




May 17th, 2022 | 14:14 CEST

Nel share with a tailwind, but what are TeamViewer and Aspermont doing?

  • Technology
  • Digitization
Photo credits: pixabay.com

Last week was disastrous for many technology stocks. In this environment, the Nel share showed strength and yesterday, it also performed positively in a relatively weak environment. That is because there is currently a tailwind for the hydrogen specialist from a wide variety of places: analysts, the European Union and even a king. At least analysts are also convinced of Aspermont. After the positive figures, investors are hoping for new impetus from the technology company's presentation at a virtual investor conference. At TeamViewer, analyst comments are mixed, but the price targets are attractive.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: NEL ASA NK-_20 | NO0010081235 , TEAMVIEWER AG INH O.N. | DE000A2YN900 , ASPERMONT LTD | AU000000ASP3

Table of contents:


    Aspermont with news on Thursday?

    After good half-year figures, analysts at GBC have confirmed the price target of EUR 0.07. The experts expect a strong full-year result. Currently, the share of the Australian Company is quoted at EUR 0.012, and the market capitalization is just above EUR 30 million. Aspermont has successfully evolved from publisher of Mining Journal and Mining Magazine to a digital company. The decisive asset is the collected data pool of around 8 million decision-makers from the mining, energy and agriculture industries. Based on a XaaS model with recurring revenues, the Australians offer high-quality content for corporate customers. In the "Data" area, user behaviour patterns are marketed, and leads are generated. In the "services" area, the Company offers services such as content creation, advertising, sponsoring and events. The subscription model enables predictable cash flows and premium content generates additional income. At the end of March, the physical conference business also started up again with the organization of the "Future of Mining". In this area, revenues of AUD 1 million are expected again in the current year.

    Overall, Aspermont increased sales in the second quarter by 39% to EUR 3.21 million compared to the same period last year. Gross profit climbed 43% to EUR 2.08 million. According to analysts at GBC, the gross margin was 65% and is expected to climb to 72% for the full year 2022. Currently, investors are waiting for the first deals under the joint venture "Blue Horseshoe". This digital platform for raising capital marked the Company's entry into the fintech business. Here, institutional investors are given the opportunity to invest in companies. There may be more on this already on Thursday, and then the Company will present at the virtual International Investment Forum. Free registration is available here.

    Nel: The EU, analysts and king provide tailwind

    Nel could convince recently with quarterly figures and the outlook. Because for the analysts of the RBC, the conversions of Nel were too low and the costs too high. Nevertheless, Nel is one of the most promising companies in the green hydrogen sector. Therefore, the analysts have confirmed their "Outperform" recommendation with a price target of NOK 24. The share is currently trading at NOK 13. Goldman Sachs also sees a price target of NOK 24 and recommends the Nel share as a "Buy". The hydrogen specialist has met analyst expectations, and rising order backlogs underpin the growth plans. Nel is currently also receiving support from politicians. Electrolysis capacities for hydrogen production are to be massively expanded in Europe. To this end, the European electrolyzer industry and the European Commission signed a declaration last week as part of the EU plan to make Europe independent of Russian fossil fuels. Nel CEO Jon André Løkke said, "The demand for green hydrogen is growing extremely fast. We are pleased with the European Commission's willingness to support us in achieving our common goals for green hydrogen production and expanding electrolyzer production capacity."

    Nel can also count on royal support. At the very least, Spain's King Felipe VI was present at the inauguration of what Nel claims is the largest plant for the production of green hydrogen for industrial use in Europe. The plant is operated by Nel and the Spanish Iberdrola Group. It will be able to produce 3,000 tons of green H2, most of which will be destined for a nearby plant owned by the chemical company Fertiberia, which will use the hydrogen as a raw material for ammonia production, also reducing natural gas consumption. A true lighthouse project for Nel. Nel CEO Jon André Løkke: "This is truly the 'king of electrolyzers' and shows what we can achieve in the production of green hydrogen for European industry."

    TeamViewer: Analysts remain cautious

    The TeamViewer share also held up well in last week's tech sell-off. Analysts tend to be cautious, but price targets are above the share's current level. Analysts at Bankhaus Metzler have confirmed their buy recommendation for the German software company. TeamViewer has had a good start to 2022. In particular, the strong development with major customers was highlighted. Nevertheless, the analysts reduced the price target from EUR 23 to EUR 18. That was due to the changing interest rate environment and lower industry valuations. From UBS' point of view, TeamViewer had a relatively weak start to the year. Subscriber growth was not satisfactory. However, analysts at the major Swiss bank praised TeamViewer's cost control. Overall, the " Neutral " rating was confirmed with a price target of EUR 16.20. TeamViewer stock is currently trading at EUR 12.50.


    Investors need strong nerves at the moment. At least there is positive newsflow at Nel, even if the really big orders are missing. At Aspermont, investors are hoping for new momentum on Thursday. TeamViewer seems to be on the right track in terms of costs.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read